Tested against 9,412 recent clinical isolates, cefotaxime exhibited 8 to 64 times greater activity against the Enterobacteriaceae than did cephalothin and two to four times greater activity against Pseudomonas aeruginosa, but only one-half to one-eighth the activity of cephalothin against staphylococci. In the first portion of this study, the clinical isolate MIC study, the 9,412 organisms tested were consecutive clinical strains isolated by six participating laboratories during a 45-day period as described previously (6, 7). A twofold dilution protocol was used for each antibiotic, ranging from 0.5 to 32 ,ug/ml. Daily, each participating laboratory tested quality control organisms which included Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922), and Pseudomonas aeruginosa (ATCC 27853). The results of these fell within the mode ± 1 dilution in more than 97% of tests.
Cefotaxime (formerly HR 756) is a new cephalosporin agent much acclaimed for its broad spectrum of in vitro antimicrobial activity (2, 3, 5, (11) (12) (13) and its beta-lactamase resistance and beta-lactamase inhibitory activity (5, 6, 8) . Interpretive zone standards for the disk diffusion susceptibility testing of cefotaxiime have been recently proposed (1) and include the use of 5-or 30-,ug disks, depending on the organism being tested. This report summarizes our disk diffusion susceptibility data on cefotaxime and proposes somewhat different tentative interpretive zone standards, based on the distribution of minimal inhibitory concentrations (MICs) among the various pathogens whose infections are likely to be treated with cefotaxime, achievable serum levels of the drug, and statistical considerations.
MATERIALS AND METHODS
Cefotaxime was supplied by Hoechst-Roussel Pharmaceuticals, Inc., Somerville, N.J. Cephalothin laboratory-standard powder was provided by Eli Lilly Research Laboratories, Indianapolis, Ind. Both compounds were diluted in Mueller-Hinton broth supplemented with calcium (50 mg/liter) and magnesium (25 mg/liter) or included in Mueller-Hinton agar plates, as previously described in detail (6, 7) .
In the first portion of this study, the clinical isolate MIC study, the 9,412 organisms tested were consecutive clinical strains isolated by six participating laboratories during a 45-day period as described previously (6, 7) . A twofold dilution protocol was used for each antibiotic, ranging from 0.5 to 32 ,ug/ml. Daily, each participating laboratory tested quality control organisms which included Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922), and Pseudomonas aeruginosa (ATCC 27853) . The results of these fell within the mode ± 1 dilution in more than 97% of tests.
The second portion of the study was a regression analysis of 420 clinical bacterial isolates obtained from six of the collaborating laboratories. These included 85 strains of P. aeruginosa, 28 Pseudomonas species, 15 Acinetobacter calcoaceticus var. anitratus, 25 Escherichia coli, 50 Enterobacter species, 25 Klebsiella pneumoniae, 25 Serratia species, 20 Citrobacter species, 10 Salmonella species, 25 Proteus mirabilis, 55 indole-positive Proteus and Providencia species, 49 Staphylococcus aureus, and 8 Streptococcus faecalis. In this phase, the twofold dilution sequence included cefotaxime and cephalothin concentrations of 0.125 to 64 Ag/ml. Cefotaxime 30-and 5 ug disks and cephalothin 30-Ag disks were prepared by Difco Laboratories, Detroit, Mich. These disks had a mean assay of 110.5% of stated potency by the disk-plate procedure. The disk diffusion susceptibility tests were perforned, according to the latest procedure published by the National Committee for Clinical Laboratory Standards CEFOTAXIME ACTIVITY AND DISK STUDY organism were plotted as scattergrams. Regression analyses were made by the formula of least squares as adapted for computer computation. In addition, analyses were performed by the error rate-bounded method of Metzler and DeHaan (9) . Cross-resistance analyses comparing cefotaxime, cephalothin, cefamandole, and cefoxitin were also performed, using the 420 strains listed above.
RESULTS
The susceptibility of 9,412 clinical aerobic and facultatively anerobic isolates to cefotaxime in this study was high, and the results shown in Table 1 and Fig. 1 and 2 generally agree with previously published reports (2, 5, 11, 13) . Each major organism group had a characteristic MIC distribution, often with little overlap (Fig. 2) . Over 91% of Enterobacteriaceae were inhibited by c0.5 ug of cefotaxime per ml, which was significantly less than those of cephalothin (>32 ,ug/ml for each).
The 420 strains used in the regression analysis study had an MIC distribution for these major groups of organisms comparable to those found among current clinical isolates (Fig. 2) .
Cross-resistance analysis of cefotaxime, cephalothin, cefamandole, and cefoxitin is summarized in Table 2 4 . Correlation between MICs and zone diameter, using 30-pg cefotaxime disks. Values outside the broken line were excluded from the regression analysis. Horizontal lines represent proposed MIC resistant (upper line) and susceptible (lower line) breakpoints. Vertical lines represent theproposed zone size susceptible (right line) and resistant (left line) breakpoints as determined by the error rate-bounded method (9) . (Slope = -0.323, y-axis intercept = 1,121 pg/ml, correlation coefficient = 0.87.) levels well above this are achievable in the serum; e.g., 2 g given intravenously over 15 min produces peak levels of 160,ug/ml (3). (ii) The majority of P. aeruginosa isolates would then fall into the indeterminate category of 16 to 32 ug/ml. Since it is not yet known how P. aeruginosa infections will respond in vivo to cefotaxime, it may be best to refer this category tentatively as indeterminate rather than intermediate.
It is now well recognized that the class disk concept is no longer valid for all cephalosporins. Of the 420 isolates used for the disk diffusion analysis, all strains that were resistant to 516 jig of cefotaxime per ml were also resistant to cephalothin, cefamandole, and cefoxitin. However, 29% of these strains were resistant to 516 ,ug of cephalothin per ml, 22% were resistant to 516,ig of cefamandole per ml, and 24% were resistant to 516 ,ug of cefoxitin per ml while being susceptible to c8 jig of cefotaximne per ml. Therefore, the disks of neither cephalothin nor the two second-generation drugs would be appropriate for predicting cefotaxime susceptibility. Examination of the cefotaxime regression plot for the 5-jig disk (Fig. 3) shows that 68% of strains inhibited by 16 and 32 jug/ml gave no zones of inhibition around the 5-jig disk, rendering this disk essentially useless for determining the indeterminate category. On the other hand, all of these strains had zones of inhibition around the 30-jig disk (Fig. 4) there is no evidence yet to suggest that an Escherichia coli strain, for example, whose cefotaxime MIC is 25 jg/ml will respond any differently than a P. aeruginosa strain with the same MIC. Therefore, there is no reason at this time to propose two separate interpretive criteria. The more meaningful and significant consideration is the differentiation between organisms of any species whose cefotaxime MIC is greater than or less than 25 ig/mli. The use of the 30-jig disk alone clearly accomplishes this.
Although the cefotaxime regression lines calculated and drawn on Fig. 3 and 4 are straight lines, it is apparent by examining the scattergram that the actual distribution tends to be parabolic at the more susceptible end of the curve. This is more striking with the 30-,ug cefotaxime disk than with the 5-jig disk. If the susceptible MIC breakpoint were lower (e.g., 1 jug/ml), then the 30-jig disk would be unable to distinguish between the susceptible and indeterminate categories. In fact, in the region of the two MIC breakpoints selected, the regression line with the 30-jig disk is straight and permits the best categorization by the disk diffusion test.
The inability to differentiate MICs of 2 jug/ml from those of 0.25 jig/ml is inconsequential since both are clearly in the susceptible category, an intrinsic limitation of the disk diffusion test.
In summary, the tentative interpretive standards for cefotaxime disk susceptibility testing by the NCCLS procedure (10) that we propose are: disk content, 30 jug; susceptible zone size, s23 mm; indeterminate zone size, 15 to 22 mm; resistant zone size, c14 mm. The advantages of these are as follows. (i) A single disk is used for all rapidly growing facultative and aerobic bacteria, which clearly delineates the three standard categories of susceptibility expected from disk diffusion tests. (ii) With the exception of A. calcoaceticus var. anitratus, the major portion of common clinical species is distributed in single susceptibility categories: Enterobacteriaceae and S. aureus, susceptible; P. aeruginosa, indeterminate; and enterococci, resistant. The major objection to the use of the 30-,jg disk mentioned previously (1) is that the zone sizes of many Enterobacteriaceae would be so large that they would interfere with the testing of adjacent antibiotics. Yet the data presented in this report (1) showed only a 3-mm difference in maximum zone size for the two disks (35 mm for 5-jig disk versus 38 mm for 30-jig disk). Our data showed a difference of only 2 to 3 mm between the mean zone diameter of the two disks at MICs of ;0.5 jig/ml. Only 8% of strains tested gave zone sizes 92 FUCHS ET AL.
on November 2, 2017 by guest http://aac.asm.org/ Downloaded from greater than 35 mm with the 30-,ug disk. We do not believe that this poses a significant enough problem to warrant a two-disk standard for this agent, and that the problem can be largely abrogated by judicious positioning of antibiotic disks on the agar plate.
It should be emphasized that these proposed standards should be considered tentative. The three major considerations in establishing interpretive standards for disk susceptibility have been discussed in detail elsewhere (A. Barry et al., submitted for publication). Two of these factors (MIC distribution of clinical isolates likely to be treated, and achievable drug serum levels) have been used in establishing the above proposed standards. The third major factor, clinical experience in the therapy of different infections by different microbes, was not used because such data are not yet available. It is this deficiency that makes these proposed criteria tentative. The proposed susceptible breakpoint at this time appears to be reliable and firm. The breakpoint for resistance is the one most in question and must await the outcome of clinical trials. Although cefotaxime serum levels of 16 and 32 ,ug/ml are readily exceeded, the majority of clinical isolates requiring these levels for growth inhibition in vitro are P. aeruginosa and other gram-negative, nonfermenting bacteria. Until clinical studies confirm or refute the efficacy of cefotaxime in infections by such microbes, we consider MICs and zone sizes in the intermediate zone as indeterminate.
